Arvinas Inc. (ARVN)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish
Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC platform. Despite Veppanu's approval for ESR1-mutated breast cancer, ARVN's share price remains near cash value, reflecting market skepticism about future revenues. ARVN's pipeline includes five early-stage programs and a Novartis-partnered asset, but high R&D costs and uncertain milestones temper near-term upside.
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript
Arvinas Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Madelyn D. Purcell Pfizer Inc | 3.46M | $66.29M | $30.12M | -$36.16M | -54.55% |
 Curtis Ellergodt Rothschild Investment LLC | 262 | $2,268 | $2,280.71 | $12.71 | 0.56% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 200 | $2,120 | $1,741 | -$379 | -17.88% |
| BG Bart Gancher Intech Investment Management LLC | 18,106 | $128,791.62 | $158,246.44 | $29,454.82 | 22.87% |
 Anthony Scaramucci SkyBridge Capital II LLC | 2.8M | $25.37M | $25.81M | $432,300 | 1.7% |
Arvinas Inc. (ARVN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Arvinas Inc. ever had a stock split?
Arvinas Inc. Profile
| Biotechnology Industry | Healthcare Sector | Randy Teel CEO | NASDAQ (NGS) Exchange | 04335A105 CUSIP |
| US Country | 246 Employees | - Last Dividend | - Last Split | 27 Sep 2018 IPO Date |
Overview
Arvinas, Inc. is a pioneering clinical-stage biotechnology firm focused on creating innovative therapies aimed at the degradation of disease-causing proteins. By designing proteolysis targeting chimeras (PROTAC) targeted protein degraders, Arvinas takes advantage of the body's own protein disposal mechanism to eliminate harmful proteins. Since its inception in 2013 and based in New Haven, Connecticut, Arvinas has established significant collaborations with industry leaders such as Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. These partnerships aim to bolster the development and potential commercialization of its groundbreaking therapies.
Products and Services
- Bavdegalutamide and ARV-766
- ARV-471
These are investigational, orally bioavailable PROTAC protein degraders designed specifically for the treatment of men with metastatic castration-resistant prostate cancer. Currently, these products are under Phase 1/2 clinical trials, demonstrating Arvinas, Inc.'s commitment to addressing this challenging health issue through innovative therapeutic solutions.
ARV-471 represents a pioneering approach as an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader. It's crafted for patients with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. With ARV-471 advancing to Phase 3 clinical trials, it underscores the company's focus on leveraging its proprietary technology to combat severe and widespread forms of cancer, offering hope for more effective treatments.
